Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
In ancient times, one highly abrasive depilatory paste consisted of an admixture of slaked lime, water, wood-ash and yellow orpiment (arsenic trisulfide); In rural India and Iran, where this mixture is called vajibt, it is still commonly used to remove pubic hair. In other cultures, oil extracted from unripe olives (which had not reached one-third of their natural stage of ripeness) was used to remove body hair. During the medieval period, Catholic women were expected to let their hair grow long as a display of femininity, whilst keeping the hair concealed by wearing a wimple headdress in public places. The face was the only area where hair growth was considered unsightly; 14th-century ladies would also pick off hair from their foreheads to recede the hairline and give their face a more oval form. From the mid-16th century, it is said when Queen Elizabeth I came to power, she made eyebrow removal fashionable. By the 18th century, body hair removal was still considered a non-necessity by European and American women. But in 1760, when the first safety straight razor appeared for men to safely shave their beard and not inadvertently cut themselves, some women allegedly used this safety razor too. It was invented in Paris by the French master cutler Jean-Jacques Perret, author of La pogonotomie, ou L'art d'apprendre à se raser soi-même (Pogonotomy, or The Art of Learning to Shave). It was not until the late 19th century that women in Europe and America started to make hair removal a component of their personal care regime.
=== DHIS 1.3 and 1.4 === The DHIS version 1 series goes back to 1996 and was developed on the Microsoft Access platform consisting of VBA for the interface or program logic (front-end), Access as a database (back-end), Excel for reporting and Windows as the OS. DHIS 1.4 (from 2005) is a significant overhaul of the version 1.3 database structure, using various output formats for reporting. It bridges the gap between DHIS 1.3 and 2.
=== Supersonic spray === Supersonic acceleration of droplets through a Laval nozzle was used to deposit reduced graphene oxide on a substrate. The energy of the impact rearranges those carbon atoms into flawless graphene.
=== Coronary heart disease risk === Arterial damage results from white blood cell invasion and inflammation within the wall. CRP is a general marker for inflammation and infection, so it can be used as a very rough proxy for heart disease risk. Since many things can cause elevated CRP, this is not a very specific prognostic indicator. Nevertheless, a level above 2.4 mg/L has been associated with a doubled risk of a coronary event compared to levels below 1 mg/L; however, the study group in this case consisted of patients who had been diagnosed with unstable angina pectoris; whether elevated CRP has any predictive value of acute coronary events in the general population of all age ranges remains unclear. Currently, C-reactive protein is not recommended as a cardiovascular disease screening test for average-risk adults without symptoms. The American Heart Association and U.S. Centers for Disease Control and Prevention have defined risk groups as follows:
Sources: en.wikipedia.org
=== Extracellular matrix adhesion and signaling === Integrin alpha-1 (ITGA1), when linked with Integrin beta-1 (ITGB1), forms the α1β1 Integrin receptor. The α1β1 is a transmembrane extracellular matrix (ECM) receptor that mediates cell adhesion and intracellular signaling. By binding collagen and laminin, ITGA1 allows cells to sense and respond to changes in the ECM. These interactions are how ITGA1 regulates cell-matrix adhesion, focal adhesion formation, ECM organization, and downstream pathways controlling cell survival, proliferation, migration, and differentiation. The molecular functions of ITGA1 include collagen binding, collagen-mediated cell-matrix adhesion, protein interactions involved in signaling pathways, and localizations to the cell surface, plasma membrane, focal adhesions, and integrin complexes. These attributes aid in its function as a key mediator of ECM-dependent cellular communication.
Eli Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax), which was approved by the US Food and Drug Administration (FDA) for the treatment of depressive episodes of bipolar I disorder in 2003 and for treatment-resistant depression in 2009.
The One Big Beautiful Bill Act (OBBBA), or the Big Beautiful Bill (P.L. 119-21), is a U.S. federal statute passed by the 119th United States Congress containing tax and spending policies that form the core of President Donald Trump's second-term agenda. The bill was signed into law by Trump on July 4, 2025. Although the Act is popularly referred to as the One Big Beautiful Bill Act, this official short title was removed from the bill during the Senate amendment process. Therefore, the law has no official short title. The OBBBA contains hundreds of provisions. It permanently extends the individual tax rates Trump signed into law in 2017, which were set to expire at the end of 2025. It raises the cap on the state and local tax deduction to $40,000 for taxpayers making less than $500,000, with the cap reverting to $10,000 after five years. The OBBBA includes several tax deductions for tips, overtime pay, auto loans, and creates Trump accounts, allowing parents to create tax-deferred accounts for the benefit of their children, all set to expire in 2028. It includes a permanent $200 increase in the child tax credit, a 1% tax on remittances, and a tax hike on investment income from college endowments. It phases out some clean energy tax credits that were included in the Biden-era Inflation Reduction Act, and promotes fossil fuels over renewable energy. It increases a tax credit for advanced semiconductor manufacturing and repeals a tax on firearm silencers. It raises the debt ceiling by $5 trillion while making a significant 12% cut to Medicaid spending.
Sources: en.wikipedia.org
Pauling also criticised the Mayo Clinic studies because the controls were taking vitamin C during the trial, and because the duration of the treatment with vitamin C was short; Pauling advocated continued high-dose vitamin C for the rest of the cancer patient's life whereas the Mayo Clinic patients in the second trial were treated with vitamin C for a median of 2.5 months. Ultimately the negative findings of the Mayo Clinic studies ended general interest in vitamin C as a treatment for cancer. Despite this, Pauling continued to promote vitamin C for treating cancer and the common cold, working with The Institutes for the Achievement of Human Potential to use vitamin C in the treatment of brain-injured children. He later collaborated with the Canadian physician Abram Hoffer on a micronutrient regime, including high-dose vitamin C, as adjunctive cancer therapy. A 2009 review also noted differences between the studies, such as the Mayo Clinic not using intravenous Vitamin C, and suggested further studies into the role of vitamin C when given intravenously. Results from most clinical trials suggest that modest vitamin C supplementation alone or with other nutrients offers no benefit in the prevention of cancer.
7-Eleven first opened in Hong Kong in 1981, when it was a British colony. As of July 2019, it operates as a subsidiary of the DFI Retail Group (formerly Dairy Farm International). It is popularly called Tsat¹-zai² (七仔, meaning "little seven") or Tsat¹-sap⁶-jat¹ (七·十一, meaning "seven eleven"). As of 2012, 7-Eleven had 964 stores in Hong Kong, of which 563 were operated by franchisees. Hong Kong reportedly has the second-highest density of 7-Eleven stores, after Macao. All 7-Eleven stores in Hong Kong accept the ubiquitous Octopus card as a method of payment. They also accept payments for utility bills and public housing rent. In November 1980, Southland Corporation and Hong Kong conglomerate Jardine Matheson signed a franchise agreement to bring 7-Eleven to the territory. The first 7-Eleven shop opened in Happy Valley on April 3, 1981. The chain expanded aggressively across Hong Kong throughout the 1980s. The 50th store opened in Kwai Chung on October 6, 1983, while the 200th was inaugurated by Simon Keswick at Tai Po Centre on May 7, 1987. The stores were sold to Dairy Farm, part of Jardine Matheson, in 1989. Octopus card readers were introduced in all 7-Eleven stores in July 1999, although at first these could only be used to add value to the card. In September 2004, the number of locations in Hong Kong was substantially boosted when Dairy Farm acquired Daily Stop, a rival convenience store chain, from SCMP Retailing (HK).
There are large wealth disparities, and many post-soviet economies are described as oligarchic. Since the dissolution of the Soviet Union, annual polling by the Levada Center has shown that over 50% of Russia's population regretted this event, with the only exception to this being in 2012 when support for the Soviet Union dipped below 50 percent. A 2018 poll showed that 66% of Russians regretted the fall of the Soviet Union, setting a 15-year record, and the majority of these regretting opinions came from people older than 55. In 2020, polls conducted by the Levada Center found that 75% of Russians agreed that the Soviet era was the greatest era in their country's history. According to the New Russia Barometer (NRB) polls by the Centre for the Study of Public Policy, 50% of Russian respondents reported a positive impression of the Soviet Union in 1991. This increased to about 75% of NRB respondents in 2000, dropping slightly to 71% in 2009. Throughout the 2000s, an average of 32% of NRB respondents supported the restoration of the Soviet Union. In a 2021 poll, a record 70% of Russians indicated they had a mostly/very favourable view of Joseph Stalin. In Armenia, 12% of respondents said the USSR collapse did good, while 66% said it did harm. In Kyrgyzstan, 16% of respondents said the collapse of the USSR did good, while 61% said it did harm. In a 2018 Rating Sociological Group poll, 47% of Ukrainian respondents had a positive opinion of Soviet leader Leonid Brezhnev, who ruled the Soviet Union from 1964 to 1982, while viewing Lenin, Stalin, and Gorbachev very negatively.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.